Clinical Trials Browser

Active not recruiting × Carcinoma, Non-Small-Cell Lung × durvalumab × Clear all

NCT05450692 2026-04-16

LATIFY

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05925530 2026-04-16

MDT-BRIDGE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06732401 2026-04-13

CLEAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04612751 2026-04-06

TROPION-Lung04

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04245514 2026-04-02

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06008093 2026-03-30

TRITON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06606847 2026-03-18

LADOGA

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05687266 2026-03-13

AVANZAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05170204 2026-03-06

HORIZON 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05941897 2026-03-05

LOTOS

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04716946 2026-03-04

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

Phase 3 Active not recruiting

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT03819465 2026-02-11

MAGELLAN

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03965468 2026-02-09

CHESS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03141359 2026-02-05

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Phase 2 Active not recruiting

61 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05206812 2026-01-27

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05221840 2026-01-27

PACIFIC-9

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03833154 2026-01-26

PACIFIC-4

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04748419 2026-01-22

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03999710 2025-11-28

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3 Active not recruiting

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03620669 2025-08-15

1st Line Durvalumab in PS 2 NSCLC Patients

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02273375 2025-08-12

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05298423 2025-08-01

KEYVIBE-006

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03148327 2025-07-15

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04062708 2025-07-08

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04905316 2025-06-17

CHORUS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 3 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04786093 2025-02-13

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04597671 2025-01-29

NVALT28

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT01993810 2024-12-18

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04392505 2024-02-29

DART

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms